A5054003419- Cancer, Lipids, and Metabolism
- Estrogen and related hormone effects
- Endoplasmic Reticulum Stress and Disease
- Mechanisms of cancer metastasis
- Neuroblastoma Research and Treatments
- RNA modifications and cancer
- Protein Degradation and Inhibitors
- Liver Disease Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Ubiquitin and proteasome pathways
- Glioma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Cancer-related molecular mechanisms research
- RNA Research and Splicing
- Cell death mechanisms and regulation
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Genital Health and Disease
- Neuroscience and Neuropharmacology Research
- Cancer-related Molecular Pathways
- Calcium signaling and nucleotide metabolism
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cervical Cancer and HPV Research
The University of Texas Health Science Center at San Antonio
2023-2024
The University of Texas Health Science Center at Houston
2023-2024
The University of Texas at San Antonio
2023-2024
Central South University
2023
Second Xiangya Hospital of Central South University
2023
Abstract Of all gynecologic cancers, epithelial-ovarian cancer (OCa) stands out with the highest mortality rates. Despite efforts, 90% of individuals who receive standard surgical and cytotoxic therapy experience disease recurrence. The precise mechanism by which leukemia inhibitory factor (LIF) its receptor (LIFR) contribute to progression OCa remains unknown. Analysis databases revealed that elevated expression LIF or LIFR was associated poor progression-free survival patients a predictor...
<p>Figure S1. Levels of PELP1 expression in 6 HCC cell lines.</p>
<p>Figure S2. SMIP34 treatment downregulates liver specific genes, MYC and E2F pathway targeted genes in HCC cells.</p>
Abstract Glioblastoma (GBM) is the most prevalent and aggressive type of adult brain tumors with low 5-year overall survival rates. Epidemiologic data suggest that estrogen may decrease tumor growth, receptor beta (ERβ) has been demonstrated to exert antitumor functions in GBM. The lack potent, selective, permeable ERβ agonist promote its action limiting therapeutic promise ERβ. In this study, we discovered Indanone tetralone-keto or hydroxyl oximes are a new class agonists. Because high...
Abstract Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related deaths in United States, with a median survival period approximately 10 months. There an urgent need for development effective targeted therapies treatment HCC. Proline-, glutamic acid- and leucine-rich protein 1 (PELP1) signaling implicated progression many cancers, although its specific contribution to HCC not yet well understood. Analysis TCGA gene expression data sets immunohistochemistry analysis tissue...
Endometrial cancer (ECa) is the most common female gynecologic cancer. When comparing two histological subtypes of endometrial cancer, Type II tumors are biologically more aggressive and have a worse prognosis than I tumors. Current treatments for ineffective, new targeted therapies urgently needed. LIFR its ligand, LIF, been shown to play critical role in progression multiple solid cancers therapy resistance. The LIF/LIFR ECa, on other hand, unknown. We investigated signaling ECa tested...
Abstract Background: Ovarian cancer (OCa) is the deadliest kind of gynecologic in United States. The long-term survival rate for OCa less than 20% after five years. Intra-tumoral and inter-tumoral heterogeneity implicated tumor resistance to conventional therapies unsatisfactory clinical outcomes. Addressing these issues necessitates innovative that target intrinsic common vulnerabilities within OCa. Recent studies have highlighted high basal level endoplasmic reticulum stress (ERS) as a...
Abstract Introduction: Of all gynecologic cancers, epithelial ovarian cancer (OCa) stands out with the highest mortality rates. Despite efforts, 90% of individuals who receive standard surgical and cytotoxic therapy experience disease recurrence. The potential involvement leukemia inhibitory factor (LIF) its receptor (LIFR) in progression OCa is still obscure. In this study, we examined mechanisms by which disruption LIF/LIFR autocrine loops contributes to cell death cells. Methods:...
Abstract Background: Inflammatory breast cancer (IBC) is a rare but incredibly aggressive subtype of (BC). IBC accounts for 2-4% all occurrences and results in 7-10% cancer-related deaths. only partially treatable with current therapies such as chemotherapy, surgery, radiotherapy. Identification novel therapeutic targets urgently required. The main organelle the synthesis, folding, modification proteins called endoplasmic reticulum (ER). Since elevated basal ER stress (ERS) usually found...
<p>Supplementary Fig.S1 shows scheme for synthesis of ER beta agonist CIDD-0149897</p>
<p>Supplementary Fig.S1 shows scheme for synthesis of ER beta agonist CIDD-0149897</p>
<p>Supplementary Fig.S2 shows data specificity of CIDD-0149897 using ER beta KO cells.</p>
<p>Supplementary Fig.S3 shows efficacy of CIDD-0149897 combination therapy.</p>
<div>Abstract<p>Glioblastoma (GBM) is the most prevalent and aggressive type of adult brain tumors with low 5-year overall survival rates. Epidemiologic data suggest that estrogen may decrease tumor growth, receptor beta (ERβ) has been demonstrated to exert anti-tumor functions in GBM. The lack potent, selective permeable ERβ agonist promote its action limiting therapeutic promise ERβ. In this study, we discovered Indanone tetralone-keto or hydroxyl oximes are a new class ER...
<p>Supplementary Fig.S3 shows efficacy of CIDD-0149897 combination therapy.</p>
<p>Supplementary Fig.S2 shows data specificity of CIDD-0149897 using ER beta KO cells.</p>
<div>Abstract<p>Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related deaths in United States, with a median survival period approximately 10 months. There an urgent need for development effective targeted therapies treatment HCC. Proline-, glutamic acid–, and leucine-rich protein 1 (PELP1) signaling implicated progression many cancers, although its specific contribution to HCC not yet well understood. Analysis The Cancer Genome Atlas gene expression data...
<p>Analysis of global transcriptional changes in <i>PELP1</i>-KD HCC cells. Volcano plot differentially expressed genes with PELP1-KD Hep3B cells is displayed (<i>n</i> = 3; <b>A</b>). PELP1-downregulated pathways were identified using gene signature (<b>B</b>). Gene set enrichment analysis plots show negatively enriched by (<b>C</b>). Heatmap images the specific affected (<b>D</b>). RT-qPCR was used to validate...
<p>PELP1 expression is upregulated in HCC, and high PELP1 associated with poor survival of patients HCC. Data obtained from TNMplot shows increased HCC (<b>A</b>). The results TCGA-UALCAN database show that progression (<b>B</b>). Clinical Proteomic Tumor Analysis Consortium tumor tissues compared normal (<b>C</b>). Association protein overall was Human Protein Atlas (<b>D</b>). TMA used to investigate the 86 six liver specimens by IHC...
<p><i>PELP1</i>-KD or SMIP34 treatment suppresses HCC xenograft tumor growth <i>in vivo</i>. Hep3B–control and Hep3B–<i>PELP1</i>-KD model cells were injected subcutaneously into female (<b>A</b>, <b>D</b>, <b>G</b>) male SCID mice (<b>B</b>, <b>E</b>, <b>H</b>). Tumor volumes assessed at 3 to 5 days of intervals. volume (<b>A</b> <b>B</b>), weights...
<p>Figure S1. Levels of PELP1 expression in 6 HCC cell lines.</p>
<p>Figure S2. SMIP34 treatment downregulates liver specific genes, MYC and E2F pathway targeted genes in HCC cells.</p>
<p><i>PELP1</i>-KD/SMIP34 treatment decreased cell viability, clonogenicity, and invasiveness of HCC cells. PELP1-KD in Huh7 Hep3B lines were confirmed by Western blot (<b>A</b>). Cell viability clonogenic assays performed to assess the impact PELP1 KD on growth cells (<b>B</b> <b>C</b>). The effect <i>PELP1</i>-KD invasion was using Matrigel chamber (<b>D</b>). SMIP34 six measured MTT assay (<b>E</b>)....
<p>SMIP34 treatment blocked PELP1-mediated extranuclear signaling and decreased global protein synthesis. Huh7, SNU398, Hep3B, SNU423 cells were treated with vehicle (DMSO 0.01%) or SMIP34 (12.5 μmol/L) to examine PELP1 degradation the stability of Rix1 complex by Western blotting (<b>A</b> <b>C</b>). SNU449 μmol/L), status known downstream targets analyzed (<b>B</b>). Hep3B Huh7 E2F1 c-Myc expressions was (<b>D</b>). (5, 10, 15 μm)...